Promoter Mutations Are an Independent Predictor of Distant Metastasis in Middle Eastern Papillary Thyroid Microcarcinoma

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2022 Apr 1

PMID 35360077

Authors

Sandeep Kumar Parvathareddy

Abdul K Siraj

Kaleem Iqbal

Zeeshan Qadri

Saeeda O Ahmed

Maha Al-Rasheed

Ahmed A AlQatie

Saif S Al-Sobhi

Fouad Al-Dayel

Khawla S Al-Kuraya

Affiliations

Soon will be listed here.

Abstract

Background: Papillary thyroid microcarcinomas (PTMCs) have been attributed to the recent increased incidence of thyroid cancer. Although indolent, a subset of PTMC could potentially develop distant metastasis (DM). This study aimed to evaluate the clinico-pathological features and molecular characteristics of PTMC and identify the risk factors for DM in PTMC patients from Middle Eastern ethnicity.

Methods: We retrospectively analyzed 210 patients with histologically confirmed PTMC. Clinico-pathological associations for DM, mutation and mutation were analyzed successfully in 184 patients. Multivariate analysis was performed using Cox proportional hazards model and logistic regression analysis.

Results: Among the PTMC patients included in this cohort, DM was noted in 6.0% (11/184), whereas tumor relapse occurred in 29/184 (15.8%). Of the 11 cases with DM, lung metastasis occurred in 8 cases, bone metastasis in 2 cases and brain metastasis in 1 case. Presence of extrathyroidal extension and male sex were significantly associated with DM. Molecular analysis showed mutations to be the most frequent, being detected in 45.7% (84/184). promoter mutations were detected in 16 (8.7%) cases and were significantly associated with DM and shorter metastasis-free survival in multivariate analysis.

Conclusions: Our study indicates a surprisingly high frequency of promoter mutation in Saudi patients with PTMC. Identifying promoter mutations as an independent predictor of DM in patients with microcarcinoma could explain the inherent aggressive nature of PTMC from Middle Eastern ethnicity and magnify its role in patient risk stratification, which might help in improving therapeutic strategy for these patients.

Citing Articles

Development and validation of an interpretable machine learning model for predicting the risk of distant metastasis in papillary thyroid cancer: a multicenter study.

Hou F, Zhu Y, Zhao H, Cai H, Wang Y, Peng X EClinicalMedicine. 2024; 77:102913.

PMID: 39552714 PMC: 11567106. DOI: 10.1016/j.eclinm.2024.102913.

TERT RNAscope analysis of sub-centimetric papillary thyroid carcinomas and synchronous lymph node metastases.

Eich M, Jeske W, Zenz U, Chiapponi C, Alidousty C, Merkelbach-Bruse S Thyroid Res. 2024; 17(1):8.

PMID: 38616265 PMC: 11017548. DOI: 10.1186/s13044-024-00195-7.

PLK1 and FoxM1 expressions positively correlate in papillary thyroid carcinoma and their combined inhibition results in synergistic anti-tumor effects.

Poyil P, Siraj A, Padmaja D, Parvathareddy S, Thangavel S, Alobaisi K Mol Oncol. 2024; 18(3):691-706.

PMID: 38361222 PMC: 10920088. DOI: 10.1002/1878-0261.13610.

Loss of CDH16 expression is a strong independent predictor for lymph node metastasis in Middle Eastern papillary thyroid cancer.

Siraj A, Parvathareddy S, Al-Rasheed M, Annaiyappanaidu P, Siraj N, Lennartz M Sci Rep. 2023; 13(1):18559.

PMID: 37899424 PMC: 10613612. DOI: 10.1038/s41598-023-45882-x.

Multi-omics profiling of papillary thyroid microcarcinoma reveals different somatic mutations and a unique transcriptomic signature.

Li Q, Feng T, Zhu T, Zhang W, Qian Y, Zhang H J Transl Med. 2023; 21(1):206.

PMID: 36941725 PMC: 10026500. DOI: 10.1186/s12967-023-04045-2.

References

Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf J, Shah R . Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016; 126(3):1052-66. PMC: 4767360. DOI: 10.1172/JCI85271. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Franceschi S, Vaccarella S . Thyroid cancer: an epidemic of disease or an epidemic of diagnosis?. Int J Cancer. 2014; 136(11):2738-9. DOI: 10.1002/ijc.29311. View

Hirshoren N, Kaganov K, Weinberger J, Glaser B, Uziely B, Mizrahi I . Thyroidectomy Practice After Implementation of the 2015 American Thyroid Association Guidelines on Surgical Options for Patients With Well-Differentiated Thyroid Carcinoma. JAMA Otolaryngol Head Neck Surg. 2018; 144(5):427-432. PMC: 5876852. DOI: 10.1001/jamaoto.2018.0042. View

Jeon M, Kim W, Choi Y, Kwon H, Lee Y, Sung T . Features Predictive of Distant Metastasis in Papillary Thyroid Microcarcinomas. Thyroid. 2015; 26(1):161-8. DOI: 10.1089/thy.2015.0375. View

Brito J, Davies L . Is there really an increased incidence of thyroid cancer?. Curr Opin Endocrinol Diabetes Obes. 2014; 21(5):405-8. DOI: 10.1097/MED.0000000000000094. View

Lin K, Wang O, Zhang X, Dai X, Hu X, Qu J . The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol. 2010; 17(12):3294-300. DOI: 10.1245/s10434-010-1129-6. View

. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014; 159(3):676-90. PMC: 4243044. DOI: 10.1016/j.cell.2014.09.050. View

Fukushima T, Takenoshita S . Roles of RAS and BRAF mutations in thyroid carcinogenesis. Fukushima J Med Sci. 2006; 51(2):67-75. DOI: 10.5387/fms.51.67. View

10.

de Biase D, Gandolfi G, Ragazzi M, Eszlinger M, Sancisi V, Gugnoni M . TERT Promoter Mutations in Papillary Thyroid Microcarcinomas. Thyroid. 2015; 25(9):1013-9. DOI: 10.1089/thy.2015.0101. View

11.

Kim K, Kim E, Yoon J, Han K, Moon H, Kwak J . Preoperative prediction of central lymph node metastasis in thyroid papillary microcarcinoma using clinicopathologic and sonographic features. World J Surg. 2012; 37(2):385-91. DOI: 10.1007/s00268-012-1826-3. View

12.

Brito J, Hay I . Management of Papillary Thyroid Microcarcinoma. Endocrinol Metab Clin North Am. 2019; 48(1):199-213. DOI: 10.1016/j.ecl.2018.10.006. View

13.

Povoa A, Teixeira E, Bella-Cueto M, Batista R, Pestana A, Melo M . Genetic Determinants for Prediction of Outcome of Patients with Papillary Thyroid Carcinoma. Cancers (Basel). 2021; 13(9). PMC: 8122921. DOI: 10.3390/cancers13092048. View

14.

Liu R, Li Y, Chen W, Cong J, Zhang Z, Ma L . Mutations of the promoter are associated with aggressiveness and recurrence/distant metastasis of papillary thyroid carcinoma. Oncol Lett. 2020; 20(4):50. PMC: 7412748. DOI: 10.3892/ol.2020.11904. View

15.

Kurtulmus N, Duren M, Ince U, Yakicier M, Peker O, Aydin O . BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness. Endocrine. 2012; 42(2):404-10. DOI: 10.1007/s12020-012-9651-x. View

16.

Asa S . The Current Histologic Classification of Thyroid Cancer. Endocrinol Metab Clin North Am. 2019; 48(1):1-22. DOI: 10.1016/j.ecl.2018.10.001. View

17.

Al-Qahtani K, Tunio M, Al Asiri M, Bayoumi Y, Balbaid A, Aljohani N . Comparative clinicopathological and outcome analysis of differentiated thyroid cancer in Saudi patients aged below 60 years and above 60 years. Clin Interv Aging. 2016; 11:1169-74. PMC: 5010076. DOI: 10.2147/CIA.S107881. View

18.

Chen A, Jemal A, Ward E . Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer. 2009; 115(16):3801-7. DOI: 10.1002/cncr.24416. View

19.

Yabuta T, Matsuse M, Hirokawa M, Yamashita S, Mitsutake N, Miyauchi A . TERT Promoter Mutations Were Not Found in Papillary Thyroid Microcarcinomas That Showed Disease Progression on Active Surveillance. Thyroid. 2017; 27(9):1206-1207. DOI: 10.1089/thy.2016.0645. View

20.

Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R . Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013; 2013:965212. PMC: 3664492. DOI: 10.1155/2013/965212. View